Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen

doi:10.1016/0264-410X(96)88807-4

Vaccine

Volume 14, Issue 13, September 1996, Pages 1291-1297

https://doi.org/10.1016/0264-410X(96)88807-4 Get rights and content

Abstract

Oral administration of soluble protein antigen, ovalbumin (OVA), encapsulated by an acid-resistant acrylic polymer, induced a strong immune response in BDF₁ mice. Mice fed the encapsulated OVA showed activation of antigen-specific IgA, IgG and IgG1 isotype antibody-secreting cells which migrated to various lymphoid tissues via the common mucosal immune system traffic pathway. The highest number of antigen-specific antibody secreting cells was found in the Peyer's patches isolated from the upper segment of the small intestine, with their numbers declining along the length of the intestinal tract. Oral administration of this product suggests activation of lymphocytes exhibiting Th2 phenotype as shown by OVA-specific IgA and IgG1 isotype antibody responses. In conclusion, we demonstrated that oral administration of encapsulated soluble protein, in the absence of adjuvant, can activate the murine common mucosal immune system.

References (37)

M.E. Lamm
Cellular aspects of Immunoglobulin A
Adv. Immunol.
(1976)
J. Mestecky et al.
Common mucosal immune system and strategies for the development of vaccines effective at the mucosal surfaces
A. Mowat
The regulation of immune responses to dietary protein antigens
Immunol. Today
(1987)
J.R. McGhee et al.
The mucosal immune system: from fundamental concepts to vaccine development
Vaccine
(1992)
T.A. Ferguson et al.
Immunoregulatory properties of antigenic fragments of bovine serum albumin
Cell. Immunol.
(1983)
S.A. Moller et al.
A filter immuno-plaque assay for the detection of antibody secreting cells in vitro
J. Immunol. Meth.
(1985)
J. Mestecky et al.
Targeting and controlled release of antigens for the effective induction of secretory antibody responses
Curr. Opin. Immunol.
(1991)
D.T. O'Hagan et al.
Biodegradable microparticles for oral immunization
Vaccine
(1993)
R.L. Walker
New strategies for using mucosal vaccination to achieve more effective immunization
Vaccine
(1994)
D.T. O'Hagan
Oral immunization and the common mucosal immune system

S.W. Craig et al.

Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit

J. Exp. Med.

(1971)

P.J. Higgins et al.

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments

J. Immunol.

(1988)

M.F. Kagnoff

Oral tolerance

Monogr. Allergy

(1988)

J. Mestecky et al.

Oral immunization—past and present

Curr. Top. Microbiol. Immunol.

(1989)

J.G. Michael

The role of digestive enzymes in orally induced immune tolerance

Immunol. Invest.

(1989)

S.L. Jain et al.

Influence of gastric digestion on orally induced tolerance and immunity

M.F. Flanagan et al.

Characterization of the immune response following the oral administration of modified antigen in an adjuvant-free system

J. Immunol.

(1993)

J.G. Michael et al.

Oral administration of encapsulated allergen

Cited by (17)

Vaccination of mice against intestinal Trichinella spiralis infections by oral administration of antigens microencapsulated in methacrilic acid copolymers
2006, Vaccine
BALB/c and NIH mice have been successfully vaccinated against the intestinal nematode Trichinella spiralis by oral administration of crude larval extracts (CLE) and excretory–secretory (ES) products derived from first stage T. spiralis larvae (L1) encapsulated in microcapsules made of copolymers of the metacrylic acid (Eudragit L100). Oral vaccination stimulated the secretion of IFN-γ and inhibited the secretion of IL-4 in spleen and mesenteric lymph nodes (MLN) of BALB/c mice. In vaccinated mice the proportion of CD4+ cells increased (p < 0.05) in Peyer's patches (PP) and decreased (p < 0.05) in spleen whereas the proportion of CD19+ cells decreased (p < 0.05) in both PP and spleen, with regard to unvaccinated controls. No variation was evident for the proportion of CD8+ cells. Oral vaccination elevated the antigen-specific serum IgG1 and IgA (p < 0.05) as well as the antigen-specific IgA response in MLN (p < 0.05). It is concluded that this way of vaccination induced a concurrent Th1/ Th2 local and systemic responses that are protective and at the same time they may help balancing the strong Th2 response triggered by helminth infections.
Development of an enteric-coated pellet formulation of F4 fimbriae for oral vaccination of suckling piglets against enterotoxigenic Escherichia coli infections
2005, European Journal of Pharmaceutics and Biopharmaceutics
A multi-particulate formulation of F4 fimbriae was developed for oral vaccination of suckling piglets against enterotoxigenic Escherichia coli infections. A feasibility test showed that incorporation of F4 fimbriae in a disintegrating pellet formulation consisting of 87.5% Pharmatose^® 200 M, 2.5% Avicel^® CL 611 and 10% Explotab^® by extrusion/spheronisation and subsequent fluid bed drying resulted in the maintenance of 69±12% of the biological activity. But subsequent coating resulted in pellets with poor enteric properties, although good in vivo immunising results were obtained after administration to piglets. From the economical point of view, a pellet formulation was optimised to decrease vaccine dose and dosing frequency. After disintegration testing, pellets consisting of lactose (α-lactose monohydrate 90 mesh/β-lactose 75/25 (w/w)) and microcrystalline cellulose in a ratio of 80/20 (w/w) showed a sponge-like structure from which F4 fimbriae could be released. Coating of these pellets resulted in good enteric properties. To improve disintegrating properties of the pellets, the lactose concentration was increased or sodium carboxymethyl starch was added. But this resulted in poor enteric properties after coating. Dissolution test showed that F4 fimbriae were released from the optimised enteric-coated pellets but interaction between F4 fimbriae and the coating polymer was seen. This incompatibility leads to unpredictable in vitro quantification of F4 biological activity.
Association complexes between ovalbumin and cyclodextrins have no effect on the immunological properties of ovalbumin
2004, European Journal of Pharmaceutics and Biopharmaceutics
Delivery systems are designed to deliver necessary amounts of drugs without modifying their biological features. Cyclodextrins (CD) are potential candidates for such a role due to their ability to alter physical and chemical properties of guest molecules by the formation of inclusion/association complexes. They have already been used to stabilize and solubilize peptides and proteins of biological importance. However, no systematic study has been reported on their immunological effects upon coupling to such proteins. Herein, we prepared and characterized the association complexes between α-, β- and hydroxypropyl-β-cyclodextrin and ovalbumin (Ova). Afterward we tested the effect of CD coupling in the Ova antigenicity and the immunological effects of CD coupling on Ova oral and subcutaneous administration. Our results clearly show that CD-coupled Ova elicits the same immunological activities as uncoupled Ova. Therefore, we conclude that CDs are immunologically safe for use as delivery systems in animals.
PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems
1999, Vaccine
Novel poly(dl-lactide-co-glycolide) microparticles for oral vaccine delivery were formulated using the enteric polymers Eudragit^® L100-55 and carboxymethylethylcellulose (CMEC) as stabilisers. To serve as a control, microparticles were also produced using the conventional PVA surfactant. In all three cases the antigen, ovalbumin (OVA)-loaded microparticles produced were less than 5 μm in diameter and had a spherical, smooth rounded appearance. The presence of surfactants at the microparticle surface was demonstrated by the surface analysis techniques, XPS and SSIMS. Incubation of microparticles with solutions of pepsin or trypsin led to the removal of a proportion of the antigen associated with all three systems. However, in three CMEC-stabilised microparticle formulations and one of three Eudragit formulations, a high percentage of the associated antigen was protected from removal by a solution of pepsin at pH 1.2 compared with the PVA-stabilised microparticles. In addition, with certain CMEC and Eudragit formulations a degree of protection was also afforded to the associated OVA against removal by trypsin at pH 7.4. Following the incubation of microparticles in simulated gastric fluid a higher percentage of intact antigenic OVA was detected in microparticles stabilised using CMEC than in the PVA- and Eudragit- stabilised formulations. Oral immunisation of mice with OVA-loaded microparticles stabilised using either of the three surfactants led to the induction of specific serum IgG and salivary IgA antibodies. Significantly higher levels of specific salivary IgA antibody to OVA were measured in mice immunised with the CMEC-stabilised microparticles than with the other two formulations. This novel approach in PLG microparticle formulation may have potential in increasing the efficacy of microparticulate systems for the oral administration of vaccines.
Rapid anti-helminthic response of B lymphocytes in the intestinal mucosal tissues of rats
1999, Cellular Immunology
B cell response toTrichinella spiralis(Ts) adult antigen (Ag) was studied in rats 1–20 days postinfection. B cell recoveries from the mesenteric lymph node (MLN), Peyer's patches (PP), thoracic duct lymph (TDL), and the spleen were determined by FACS analysis and Ag-specific antibody-producing cells (Ab-pc) in these tissues were enumerated using the immunoplaque assay. Total B cell numbers increased 2–70 times from day 3 postinfection in the MLN and TDL obtained from MLN-resected rats (MX) and such proliferation was not found in the PP or the spleen. Ab-pc of all isotypes increased from day 3 in the MLN and from day 2 in the MX-TDL. Among all isotypes, IgE- and IgG1-pc showed the strongest response. Immunofluorescence study revealed that these B cells were activated in the non-PP region of the small intestine. These results indicate an early isotype switch to IgG1 and IgE production in Ts-infected small intestine.
Oral immunization with a Streptococcal pneumoniae polysaccharide conjugate vaccine in enterocoated microparticles induces serum antibodies against type specific polysaccharides
1999, Vaccine
The authors examined the antibody responses of mice orally immunized with pneumococcal polysaccharide (type 23F) or a pneumococcal polysaccharide conjugated to the outer membrane protein complex of Neisseria meningitides (23F-OMPC). These antigens were administered either in solution or entrapped within microcapsules. Only the mice receiving the encapsulated conjugate vaccine produced significant levels of anti-polysaccharide serum antibodies. These responses, observed after a second oral immunization with the conjugate, were predominantly IgG. Thus, the conversion from a T-cell-independent to a T-cell dependent response, achieved through conjugation was maintained following oral delivery. However, no local secretory IgA anti-polysaccharide response was detected in these mice indicating that while the OMPC carrier augments orally induced IgG responses, it was insufficient for the induction of secretory IgA.

View all citing articles on Scopus

View full text

ReprintActivation patterns of murine B cells after oral administration of an encapsulated soluble antigen

Abstract

Adv. Immunol.

Immunol. Today

Vaccine

Cell. Immunol.

J. Immunol. Meth.

Curr. Opin. Immunol.

Vaccine

Vaccine

Oral immunization and the common mucosal immune system

Peyer's patches: an enriched source of precursors for IgA-producing immunocytes in the rabbit

J. Exp. Med.

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments

J. Immunol.

Oral tolerance

Monogr. Allergy

Oral immunization—past and present

Curr. Top. Microbiol. Immunol.

The role of digestive enzymes in orally induced immune tolerance

Immunol. Invest.

Influence of gastric digestion on orally induced tolerance and immunity

Characterization of the immune response following the oral administration of modified antigen in an adjuvant-free system

J. Immunol.

Oral administration of encapsulated allergen

Reprint
Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen